Latest News and Press Releases

FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...

25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...

- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Press release ...

Press release       Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2...

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) --...

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...

LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...

Press release       Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug...

Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival;Data Maturity at Issue Conference Call...